“This document provides a summary of regulatory measures approved by the Pharmaceutical Committee to reduce drug use risks. Key points include:
3.Sulfanilamide and Sulfadiazine: Indications for these powders were revised for treating superficial and small infectious wounds.
These measures are aimed at improving safety, reducing risks, and ensuring proper use of medications in various formulations and indications.
Source:https://drug.fda.moph.go.th/media.php?id=666445387514650624&name=%E0%B8%A1%E0%B8%B2%E0%B8%95%E0%B8%A3%E0%B8%81%E0%B8%B2%E0%B8%A3%E0%B8%A5%E0%B8%94%E0%B8%84%E0%B8%A7%E0%B8%B2%E0%B8%A1%E0%B9%80%E0%B8%AA%E0%B8%B5%E0%B9%88%E0%B8%A2%E0%B8%87-%E0%B8%84%E0%B8%A3%E0%B8%B1%E0%B9%89%E0%B8%87%E0%B8%97%E0%B8%B5%E0%B9%88%204-67.pdf##~https://drug.fda.moph.go.th/press-release/conclude-drugcommitee/
Region: Thailand
Reach out to us and let’s unravel your Regulatory puzzle together. Unlock regulatory solutions with our global subject matter experts and tap into a wealth of regulatory intelligence.
Speak to an Expert